Advertisement


Michael Gnant, MD, on Duration of Anastrozole Treatment: Results of the ABCSG-16 Trial

2017 San Antonio Breast Cancer Symposium

Advertisement

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years of adjuvant endocrine therapy (Abstract GS3-01).



Related Videos

Breast Cancer

Keynote Lecture: Silvia C. Formenti, MD, on Converting Tumors Into in Situ Vaccines With Radiation Therapy

Silvia C. Formenti, MD, of Weill Cornell Medicine, discusses the high therapeutic potential of combining radiotherapy with immunotherapy and findings that show radiation dose and f...

Breast Cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a no...

Breast Cancer

Vered Stearns, MD, and Prudence A. Francis, MD, on ER+ Breast Cancer: Controversies in Adjuvant Treatment

Vered Stearns, MD, of Johns Hopkins University, and Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discuss two key topics in adjuvant treatment: en...

Breast Cancer

Louis Fehrenbacher, MD, on Invasive Breast Cancer: Results From the NSABP B-47 Trial

Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or doceta...

Breast Cancer

Nicholas C. Turner, MD, PhD, on Tackling Breast Cancer Diversity

Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to ...

Advertisement

Advertisement



;
Advertisement